Immunic Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Minimum Bid Price Rule

Reuters
Jun 28, 2025
Immunic Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Minimum Bid Price Rule

Immunic Inc. has announced that it received a notification from The Nasdaq Stock Market LLC indicating non-compliance with Nasdaq Listing Rule 5450(a)(1), due to its common stock's closing bid price falling below the $1.00 per share minimum for 30 consecutive business days. The company has until December 24, 2025, to regain compliance by ensuring its stock price meets the minimum requirement for at least 10 consecutive business days. If compliance is not achieved, Immunic may seek an additional compliance period. The company is actively monitoring its stock price and exploring options to address the issue, though there is no guarantee of success. The notification does not immediately affect the company's current listing on the Nasdaq Global Select Market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193805-25-000943), on June 27, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10